Clinical Trials Browser

Phase 1/2 × apatinib × Lymphoid × Clear all

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Phase 1/2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic